Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mtb72F + AS02A
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
A combination **vaccine candidate** comprising the recombinant fusion protein **Mtb72F**—a polyprotein derived from the antigens Mtb32 and Mtb39 of Mycobacterium tuberculosis—**formulated with the adjuvant AS02A**. Designed as an adjunct to Bacillus Calmette–Guérin (BCG) vaccination, the combination aims to induce a strong and long-lasting Th1-type immune response (increased IFN-γ, TNF-α, IL-2) to enhance protection against tuberculosis. In nonhuman primates and guinea pig models, Mtb72F + AS02A improved survival and promoted lesion resolution compared to BCG alone. Mtb72F/AS02A can serve as a booster following BCG vaccination and is under evaluation as a tuberculosis vaccine strategy[1][2].
- Other names
- Mtb72F + AS02AMtb72F/AS02AMtb72F-AS02AMtb-72F-AS02AMtb 72F-AS02A
02
Targets
MHC I (MHC class I})MHC II (Major histocompatibility complex class II receptor)T-cell receptor specific for Mycobacterium tuberculosis Mtb32A and Mtb39A antigensTCR-Mtb32A/Mtb39A (T-cell receptor specific for Mycobacterium tuberculosis Mtb32A and Mtb39A epitopes)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Mtb72F + AS02A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mtb72F + AS02A.